This trial is evaluating whether TSR-042 will improve 1 primary outcome and 5 secondary outcomes in patients with Endometrial Neoplasms. Measurement will happen over the course of 16 weeks.
This trial requires 51 total participants across 1 different treatment group
This trial involves a single treatment. TSR-042 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The incidence of endometrial cancer in the United States is at its highest level in the last four decades. A major decrease can be expected in the future." - Anonymous Online Contributor
"The majority of stage II disease can be cured without apparent risk during follow-up. The overall cure rate remains low, but the percentage of women with stage III/IV disease who do not relapse during follow-up is considerable." - Anonymous Online Contributor
"Endometrial cancer may present with abdominal pain, vaginal bleeding, genital mass or discharge. Lymphadenopathy may be present as a result of spread to the lymph nodes. There is a wide range of presentation of endometrial cancer, and these signs are nonspecific. There may be a wide range of diagnoses which include ovarian cancer, endometrial stroma sarcoma and endometriosis associated adenocarcinoma." - Anonymous Online Contributor
"In terms of common treatments for endometrial neoplasms, hysterectomy, and radiation are effective options. The treatment of endometrial neoplasms should focus on removal of the primary tumour." - Anonymous Online Contributor
"Endometrial carcinoma accounts for 65% of all endometrial neoplasms in our population. The data provide new insights into this enigmatic disease. The most common presenting symptom was anemia. The etiology for endometrial neoplasia may arise in early pregnancy or be a result of local immunologic damage after delivery. To evaluate the potential role for specific vaccination programs, our data should be considered in combination with the data from other countries." - Anonymous Online Contributor
"Endometrial cancer is one of the most common forms of cancer in the United States and causes many deaths annually, with approximately 500,000 cases and 20,000 deaths in 2006. Endometrial cancer is usually detected by screening. The cause of most cases is unknown. It is not known which factor causes the cancer to form. But if it occurs as the result of a cancer in another part of the body, the patient must be screened for that as well. When a doctor says your test results show endometrial neoplasia, the next thought is that an endometrial biopsy is needed to determine the cause. endometrial cancer screening in women of reproductive age who have a family history of endometrial cancer." - Anonymous Online Contributor
"Although endometrial neoplasm could be fatal if untreated, almost 80% of patients undergoing surgery for this disease will survive without chemotherapy. However, patients should be aware that the disease can be recurrent. Thus, for women who have a history of endometrial lesions, they should be monitored more closely." - Anonymous Online Contributor
"The endometrial cancer treatment is quite complicated and there is still a long way to go to figuring out effective treatment and adjuvant therapies. However, several novel approaches are getting popular and hopeful regarding endometrial cancer. Therefore, there is an update concerning what is new, but only potential treatments are shown within this article." - Anonymous Online Contributor
"TS-042 treatment exhibited significantly greater PFS (p < 0.001) and OS (p < 0.01) than control treatment. Results from a recent paper of this small clinical trial of TS-042 indicate that TS-042 is effective and well tolerated with potential clinical implications." - Anonymous Online Contributor
"Endometrial neoplasms run in families probably because of linkage of genetic defects to telomerase activation. The same association is described in primary endometrial carcinoma. However, our data did not confirm a common ancestor for endometrial and other mucinous neoplasms in the same family members." - Anonymous Online Contributor
"A diagnosis of endometrial neoplasms has become more frequent because of the increase in use of estrogen-progestin combined oral contraceptives, and the elderly women who are taking these drugs have a higher risk of endometrial neoplasms. There is a need for more awareness of the existence of endometrial neoplasms among the public and for the development of a screening test for endometrial neoplasms." - Anonymous Online Contributor
"In a recent study, findings shows that the pharmacology of TSR-042 is similar to that of the lead compound, the first-in-class anti-cancer agent BAY 1137098. The side effects observed are consistent with those seen with this agent and other targeted inhibitor agents currently in development and clinical studies. As this drug is being developed for the treatment of endometrial cancer we intend to begin a dose-finding trial of TS-042 in patients with recurrent, well-differentiated endometrial cancer." - Anonymous Online Contributor